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Human intestinal fluids (HIF)
Clinical trial
LC-MS/MS
A B S T R A C T
In a previously performed small-scale clinical study, healthy volunteers were asked to ingest an oral solution of
itraconazole (Sporanox®) containing 40% 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) (i) with or (ii) without a
standardized volume of water (240mL) after which gastrointestinal and blood samples were collected. Although
omitting water during the administration of Sporanox® resulted in noticeably higher duodenal concentrations of
itraconazole, systemic exposure was almost unaffected. It is assumed that this discrepancy can be explained by
differences in the extent of entrapment of itraconazole in the duodenum caused by differential complexation
depending on the concentration of cyclodextrins. To further substantiate this hypothesis, the quantification of
HP-β-CD concentrations in the aspirated intestinal fluids was performed by LC-MS/MS. When comparing the
intestinal concentrations of itraconazole and HP-β-CD for one single healthy volunteer (HV02) in both test
conditions, an excellent correlation was observed (Spearman’s rank coefficient of 0.96). Moreover, the data
suggest that, similar to aqueous buffer media, also in human intestinal fluids a non-linear relationship exists
between itraconazole solubility and HP-β-CD concentration (Ap-type profile; Spearman’s rank coefficient of
0.78), indicating that higher order complexes are formed at higher concentrations of HP-β-CD. This difference in
extent of entrapment in the inclusion complexes helps to understand the observed impact of water intake on
precipitation and permeation behavior of itraconazole in man. Without water intake, higher HP-β-CD con-
centrations resulted in less precipitation and increased duodenal concentrations of itraconazole. On the other
hand, the stronger interaction at higher HP-β-CD concentrations reduced the free fraction of the drug explaining
that increased intraluminal concentrations of itraconazole were not translated into an enhanced uptake. In
conclusion, quantifying the concentrations of the solubilizing agent HP-β-CD in human intestinal fluids appeared
to be of crucial importance to interpret the intraluminal behavior of an orally administered cyclodextrin-based
solution.
1. Introduction
One of the most important contemporary challenges in drug de-
velopment is the increasing proportion of active pharmaceutical in-
gredients (APIs) exhibiting poor biopharmaceutical properties [1,2].
For drugs intended for oral administration, enabling formulations are
commonly used to meet the prerequisites of attaining suitable drug
concentrations and sufficient intestinal transport at the site of absorp-
tion. While the use of excipients which affect intestinal permeability
remains controversial and usually evokes safety concerns [3,4], a con-
siderable armamentarium of established solubility enhancing techni-
ques is available to the formulation scientist [5].
To enable the non-clinical evaluation of these formulations in a
reliable manner, major efforts are ongoing to design in vitro and in silico
tools that are predictive for in vivo gastrointestinal drug behavior [6–8].
Notwithstanding the indisputable progress in this field, it is generally
recognized that the correlation between in vitro or in silico work and the
in vivo situation is sometimes flawed [9,10]. Especially for in vitro
models, it is difficult to strike the right balance between an experi-
mental design that is straightforward enough to be implemented for
screening purposes and a set-up that oversimplifies the intricate in vivo
environment. In this regard, techniques that allow gaining insight into
the gastrointestinal variables affecting drug and formulation behavior
in vivo are beneficial as they allow optimizing and validating in vitro
techniques and offer valuable data to implement in computational ab-
sorption models [11]. Among the methodologies available to study
https://doi.org/10.1016/j.ejpb.2018.06.025
Received 4 January 2018; Received in revised form 19 April 2018; Accepted 22 June 2018
⁎ Corresponding author at: Drug Delivery and Disposition, KU Leuven, Gasthuisberg O&N II, Herestraat 49 – box 921, 3000 Leuven, Belgium.
E-mail address: Patrick.augustijns@kuleuven.be (P. Augustijns).
European Journal of Pharmaceutics and Biopharmaceutics 132 (2018) 231–236
Available online 27 June 2018
0939-6411/ © 2018 Elsevier B.V. All rights reserved.
T
gastrointestinal drug disposition in vivo, intraluminal sampling has been
successfully applied to acquire information on composition of gastro-
intestinal fluids, gastrointestinal drug behavior and impact of gastro-
intestinal motility [12–14]. Monitoring gastric and/or intestinal drug
concentrations upon administration of drug products to healthy vo-
lunteers allows evaluating the in vivo performance of formulations
generating important feedback for in vitro and in silico tool develop-
ment. For instance, the administration of Zytiga® (abiraterone for-
mulated as the ester prodrug abiraterone acetate) to healthy volunteers
underscored the importance of providing dissolution media with hy-
drolytic capacity for prodrug evaluation [15]. Indeed, fast intestinal
dissolution and subsequent degradation of abiraterone acetate by hy-
drolytic enzymes triggers abiraterone supersaturation. These mechan-
isms were shown to be important for the performance of the formula-
tion.
It is obvious from the previous example that a delicate interplay
between the formulation and the gastrointestinal physiology takes place
after oral intake of a drug. Therefore, it is sometimes difficult to dis-
criminate between formulation effects and physiological processes. A
possible approach to establish a clear, unequivocal relationship be-
tween the drug concentrations measured in vivo and the formulation is
the assessment of essential excipients that may affect drug concentra-
tions. For instance, Brouwers et al. demonstrated the importance of
measuring the concentration of the solubilizing agent d-α-tocopheryl
polyethyleneglycol 1000 succinate (TPGS) in duodenal fluids aspirated
from healthy volunteers upon administration of a standard formulation
of amprenavir (Agenerase®) to explain the high intestinal concentra-
tions of amprenavir [16].
Recently, we investigated the effect of dilution (administration with
or without a glass of water) on the formulation performance of
Sporanox® oral solution which contains the antifungal agent itracona-
zole solubilized by 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) [17].
Itraconazole is a poorly soluble, basic compound and its solubility was
demonstrated to improve strongly in the presence of HP-β-CD [18]. In
addition to this formulation-based effect, the solubility of itraconazole
is also significantly influenced by pH. Indeed, in vitro and in vivo studies
clearly demonstrate a superior solubility in the pH range that is relevant
for the fasted stomach as compared to the more neutral pH range of the
small intestine resulting in itraconazole supersaturation upon gastro-
intestinal transfer [17,19–21]. In our recent work, we showed that in-
traluminal dilution of the cyclodextrin-based itraconazole formulation
with coadministered water does not affect the systemic exposure to
itraconazole, even though duodenal concentrations are reduced. It was
argued that this is most likely due to stronger entrapment of itracona-
zole in cyclodextrin complexes upon administration of Sporanox®
without water. Thorough understanding of these observations requires
insight into the concentrations of HP-β-CD in the intraluminal fluids.
The aims of the current study were therefore (i) to quantify HP-β-CD
concentrations in the intestinal fluids aspirated upon intake of Spor-
anox® by liquid chromatography-tandem mass spectrometry (LC-MS/
MS) and (ii) to explore the link between the intestinal concentrations of
itraconazole and HP-β-CD.
2. Materials and methods
2.1. Chemicals
Itraconazole and HP-β-CD (Kleptose® HPB parenteral grade,
Roquette Frères, Lestrem, France) were kindly provided by Johnson &
Johnson Pharmaceutical Research and Development (Beerse, Belgium).
Dimethyl sulfoxide (DMSO) and methanol (MeOH) were obtained from
Acros Organics (Geel, Belgium). Sodium acetate trihydrate and acetic
acid were purchased from VWR (Leuven, Belgium), while acetonitrile
(ACN) was supplied by Fisher Scientific (Leicestershire, UK). Formic
acid (≥99%) and methanol absolute (≥99.98%) were purchased from
Biosolve (Valkenswaard, The Netherlands). Ammonium formate
(≥99%) was supplied by Sigma-Aldrich (Steinheim, Germany). Water
was purified using a Maxima system (Elga Ltd., High Wycombe Bucks,
UK).
2.2. Clinical trial – study design
The duodenal samples in which the concentrations of HP-β-CD were
determined, were obtained from a clinical study recently described by
Berben et al. [17]. Despite this cross-over study was performed in 5
healthy human volunteers (HV) (3 males and 2 females aged between
22 and 27 years old), only duodenal samples from one single volunteer
(HV02) were used to measure the concentrations of HP-β-CD. Volun-
teers could only participate in the study, performed at the University
Hospitals Leuven, after a medical examination. Participation of volun-
teers suffering from gastrointestinal disorders or infectious diseases
(hepatitis B or C and HIV) was strictly forbidden, protecting the well-
being of the researchers and volunteers. Other exclusion criteria were
the regular intake of medication, frequent exposure to X-rays or a po-
tential pregnancy. The clinical study protocol (S53793) was in ac-
cordance with the declaration of Helsinki and approved by the Com-
mittee of Medical Ethics of the University Hospitals Leuven (ML7919,
EudraCT reference number 2011-005928-17) and by the Federal
Agency for Medicines and Health Products (FAHMP). All volunteers
provided written informed consent before the start of the clinical trial.
After an overnight fast (no food consumption and only drinking of
water for 12 h), two double lumen catheters (Salem Sump™ PVC Gas-
troduodenal Tube, 14Ch (4.7 mm) 108 cm, Covidien, Dublin, Ireland)
were introduced via the nose and positioned in the antrum (in front of
the pylorus) and in the duodenum (D2/D3), guided by fluoroscopy.
After an equilibration period of 20min, 20mL of Sporanox® solution
(10mg/mL; 200mg of itraconazole) was orally administered with or
without a glass of water (240mL). Subsequently, gastrointestinal fluids
were aspirated (< 4mL sampling volume) at predetermined time points
(7, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165 and 180min) for the
determination of dissolved and total concentrations of itraconazole and
the dissolved concentrations of HP-β-CD. Directly after aspiration of the
gastrointestinal fluids, pH was measured (Hamilton Knick Portamess®,
Bonaduz, Switzerland). For each individual intestinal aspirate, ther-
modynamic solubility of itraconazole was determined according the
shake-flask method. We would like to refer to the first manuscript for
the specifications of the analysis of itraconazole [17].
For the assessment of HP-β-CD, aspirated intestinal samples from
HV02 were transferred to Vrije Universiteit Amsterdam (VUA) (cfr.
Section 2.4.) according to an agreement for inter-institutional transfer
of human tissue samples.
2.3. Caco-2 permeation of itraconazole from human intestinal fluids
To evaluate the permeation potential of itraconazole from aspirated
intestinal fluids, transport of itraconazole from selected samples was
determined across Caco-2 cell monolayers immediately after aspiration.
To this end, 1.5 mL of TPGS (0.2%w/v) was applied to the basolateral
compartment and 100 µL of mucus (50mg/mL) was added to the apical
compartment, followed by the addition of 500 µL of the aspirated in-
testinal fluid. Subsequently, samples (100 µL) were time-dependently
withdrawn during 30min from the basolateral compartment. TEER
values were measured before and after the transport experiment to
demonstrate monolayer integrity. For a detailed description of the ex-
perimental conditions, we refer to Berben et al. [17].
2.4. Analysis of HP-β-CD in human intestinal fluids of the fasted state
To quantify the concentrations of HP-β-CD in the human intestinal
fluids, an LC-MS/MS method was developed. The LC-MS system con-
sisted of a Thermo Finnigan LC system (Thermo Finnigan, San Jose, CA,
USA) coupled to an ion-trap XCT 6330 mass spectrometer (Agilent
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Technologies, Palo Alto, CA, USA) equipped with an electrospray io-
nization (ESI) source. Cyclodextrin separation was performed using a
Waters Xbridge BEH C18 (3.0× 100mm; 2.5 µm; Waters, Milford, MA,
USA). The mobile phase was a mixture of 5mM ammonium formate in
water (solvent A) and methanol (solvent B). The following gradient
elution program was applied at a constant flow rate of 200 µL/min:
1min at 5% B followed by a linear change to 70% B in 1min, 6min of
isocratic elution at 70% B, a linear change to 95% B in 1min, and
isocratic elution at 95% B for 6min, after which the column was re-
equilibrated with the initial conditions (5% B) for 7min prior to the
next injection. The sample injection volume was 10 µL. Separation
temperature was set at 30 °C.
MS analysis was performed in positive ionization mode using the
following settings: ESI voltage, 3.75 kV; dry gas temperature, 320 °C;
dry gas flow rate, 6.5 L/min; nebulizer pressure, 12.5 psi; skimmer,
40 V. A maximum accumulation time of 50ms was set with a Smart ICC
of 30,000 to limit the number of accumulated ions dynamically. For
MS/MS experiments, the 1442.3m/z ion (ammonium adduct of (HP)5-
β-CD) was isolated (isolation width, 8.0m/z) and fragmentation was
performed via collision induced dissociation (CID) using an amplitude
of 0.65 V. MS and MS/MS spectra were collected between 200 and
2000m/z. Data were analyzed using the DataAnalysis software from
Bruker.
HP-β-CD eluted at about 7min, whereas retained matrix compounds
eluted between 8 and 16min. Since the concentration of HP-β-CD in the
intestinal fluids was relatively high, samples were diluted 30–500 times
in water prior to injection. Calibration curves were constructed by
adding increasing concentrations of HP-β-CD to blank human intestinal
fluid, which was diluted 30 times in water (i.e. the minimum dilution
factor required for the reliable quantification of HP-β-CD in the sam-
ples). The slopes obtained for the calibration curves were not sig-
nificantly different from the slopes obtained for measuring increasing
HP-β-CD concentrations in water, indicating matrix effects were vir-
tually absent. The linear measuring range was demonstrated between 1
and 250 μg/mL HP-β-CD (r2 of 0.995) and the method was able to de-
tect concentrations down to 0.25 μg/mL. The method showed good
intra- (n= 6) and interday (n=18, 6 consecutive injections on three
different days) repeatability with RSDs (%) between 0.2 and 0.8% for
retention times and between 4% and 8% for peak areas, respectively.
Recovery values ranged from 95% to 100% for a spiked concentration
of 200 μg/mL HP-β-CD.
2.5. Data presentation and statistical analysis
The Spearman’s rank coefficient was used to quantify the correla-
tion between the measured HP-β-CD concentrations on the one hand
and the dissolved concentrations of itraconazole or the thermodynamic
solubility on the other hand. To relate the precipitated fraction of
itraconazole to the concentration of HP-β-CD, only samples within 30
min of the tmax of itraconazole were included.
3. Results and discussion
In a previously performed small-scale clinical study, healthy vo-
lunteers were asked to ingest an oral solution of itraconazole
(Sporanox®) containing 40% HP-β-CD (i) with or (ii) without a stan-
dardized volume of water (240mL) after which gastrointestinal and
blood samples were collected at predetermined time points. Although
the intake of water resulted in substantially lower duodenal con-
centrations of itraconazole due to intraluminal dilution and increased
extent of precipitation, plasma concentrations were almost unaffected
[17]. It was hypothesized that these findings could be linked to dif-
ferences in the extent of itraconazole entrapment in cyclodextrin
complexes at different cyclodextrin concentrations [19]. Hence, a full
understanding of these observations requires insight into the con-
centrations of HP-β-CD in the intestinal fluids. Due to the limited vo-
lumes of intestinal fluids available, HP-β-CD concentrations were only
measured for a single volunteer (HV02); both test conditions (with and
without water) were included in the analysis. Average concentrations
(n= 5) of itraconazole have already been reported in a previous pub-
lication [17]; in the present manuscript, however, we specifically refer
to the concentrations of itraconazole for HV02.
3.1. Quantification of HP-β-CD in human intestinal fluids
When a clinically relevant dose (20mL) of Sporanox® solution was
administered to HV02 without water, the duodenal HP-β-CD con-
centration-time profile as determined by LC-MS/MS closely followed
the corresponding itraconazole profile, as illustrated in Fig. 1A. The
maximum concentration of HP-β-CD (81.3mg/mL=8.1%) in the
duodenum was measured 15min after the intake of the 40% HP-β-CD
solution, corresponding to the tmax for itraconazole.
When the solution was coadministered with a standardized volume
of water to the same volunteer, lower duodenal concentrations of HP-β-
CD were measured, as depicted in Fig. 1B. More specifically, the max-
imum concentration of HP-β-CD amounted to 20.5 mg/mL (=2.1%)
and was measured 90min after the oral intake of the formulation.
Unfortunately, due to the limited sample volume, the concentration of
HP-β-CD could not be determined when the maximum concentration of
itraconazole (t= 60min) was attained for this test condition (Fig. 1B,
dotted line).
Overall, when comparing the measured concentrations of
Fig. 1. Duodenal concentration-time profiles of itraconazole (squares, left y-axis) and HP-β-CD (triangles, right y-axis) following the oral intake of Sporanox® without
(A) or with water (B) to HV02. The concentration of HP-β-CD could not be measured at t= 60min which is illustrated by a dotted line (B). Concentrations of
itraconazole are adopted from Berben et al. [17] (with permission).
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itraconazole and HP-β-CD in the duodenal fluids for both test condi-
tions, an excellent correlation was observed, which was characterized
by a Spearman’s rank coefficient of 0.96, as illustrated in Fig. 2. Al-
though dissolved intestinal itraconazole concentrations can be influ-
enced by physiological factors such as pH and bile salt concentrations,
the strong correlation in Fig. 2 indicates that the HP-β-CD concentration
is the most factor component determining the itraconazole concentra-
tion in the intraluminal environment upon the oral administration of
Sporanox® solution.
Interestingly, when comparing the ratio (“without water” over
“with water”) of the area under the duodenal concentration-time curve
(AUC0-3h) for HP-β-CD and dissolved concentrations of itraconazole,
this ratio was remarkably higher for itraconazole (6.4-fold difference)
than for HP-β-CD (2.3-fold difference). The high ratio for the dissolved
concentrations of itraconazole can be explained by the reported in-
crease in precipitation of itraconazole upon water intake [17]. In con-
trast, for the total content of itraconazole (dissolved and precipitated), a
ratio (2.4-fold difference) similar to the one calculated for HP-β-CD was
observed indicating that HP-β-CD and total itraconazole were diluted to
the same extent.
Furthermore, calculated intestinal HP-β-CD concentrations, as-
suming a residual gastric volume of 50mL and a 1:1 dilution upon
gastrointestinal transfer, approach measured peak concentrations of
HP-β-CD for both test conditions: in the case of concomitant water in-
take, a concentration of 1.3% (vs. 2.1% as experimental concentration)
was calculated while for the administration of the formulation without
water, an intestinal HP-β-CD peak concentration of 5.7% (vs. 8.1% as
experimental concentration) was predicted.
3.2. Itraconazole solubility in intestinal fluids containing HP-β-CD
In addition to the concentration of itraconazole, the thermodynamic
solubility of itraconazole (24 h, 37 °C) was also determined for each
individual duodenal aspirate of HV02 [17]. As thoroughly described in
literature, in vitro experiments in water and several aqueous buffer
systems (including a pH 4 and 7 phosphate-citrate buffer) clearly de-
monstrate a positive deviation from linearity for the relationship be-
tween itraconazole solubility and concentrations of HP-β-CD, which is
known as an Ap-type profile [19,22]. Instead of a 1:1 association, this
type of profile suggests that one itraconazole molecule interacts with
several cyclodextrin units meaning that higher order complexes are
formed at higher concentrations of HP-β-CD. Additionally, Stappaerts
et al. observed similar Ap-type profiles when assessing the impact of HP-
β-CD on the solubility of itraconazole in biorelevant media including
fasted and fed state simulated intestinal media (FaSSIF/FeSSIF) [20]. As
illustrated in Fig. 3, our data suggest that such a relationship also exists
in fasted state human intestinal fluids (Spearman’s rank coefficient of
0.78).
3.3. Interpreting intraluminal drug behavior
The measured HP-β-CD concentrations in the intestinal samples
might help to understand the gastrointestinal observations upon ad-
ministration of the cyclodextrin-based solution of itraconazole with or
without a glass of water. Upon gastrointestinal transfer of the weakly
basic drug from the acidic environment of the stomach into the more
neutral environment of the small intestine, supersaturated concentra-
tions of itraconazole were observed in the duodenum, irrespective of
water intake [17]. Although supersaturation of itraconazole might be
stabilized by the presence of cyclodextrins [21,23], it is unstable from a
thermodynamic point of view and therefore the driving force for pre-
cipitation. The extent of intestinal precipitation was significantly in-
creased when the formulation was coadministered with water com-
pared to the intake as such. For HV02, for instance, the percentage of
intestinal precipitation, based on the difference of the dissolved and
total concentration-time profile (AUC0-3h) of itraconazole, amounted to
66.7% with water intake vs. 13.2% without water intake. This dis-
crepancy is most likely related to an increased intraluminal dilution of
the solubilizing cyclodextrins that are present in the formulation. In-
deed, considering the samples around the tmax of itraconazole
(± 30min), the extent of precipitation could be linked reasonably well
with the measured concentration of HP-β-CD (Fig. 4). This observation
clearly implies that, as a result of the non-linear phase-solubility profile
(Fig. 3), higher order complexes are formed at higher concentrations of
Fig. 2. Correlation between measured concentrations of itraconazole and HP-β-
CD in duodenal fluids following the oral administration of Sporanox® with
(open circles) and without (closed circles) 240mL of water to HV02.
Concentrations of itraconazole are adopted from Berben et al. [17] (with per-
mission).
Fig. 3. Itraconazole solubility in human intestinal fluids as a function of con-
centration of HP-β-CD. Circles represent an individual duodenal aspirate fol-
lowing the administration of Sporanox® solution to HV02 without (closed) and
with (open) water, respectively. Concentrations of itraconazole are adopted
from Berben et al. [17] (with permission).
Fig. 4. Percentage precipitation of itraconazole as a function of the measured
concentration of HP-β-CD in aspirated duodenal fluids. Circles represent an
individual duodenal aspirate following the administration of the formulation to
HV02 without (closed) and with (open) water, respectively. Concentrations of
itraconazole are adopted from Berben et al. [17] (with permission).
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HP-β-CD explaining the lower precipitated fraction of itraconazole at
higher concentrations of HP-β-CD. Upon strong intraluminal dilution
due to water intake, weaker complexes are formed and itraconazole
precipitation is more pronounced. To quantify the difference in affinity
between itraconazole and HP-β-CD at varying concentrations of HP-β-
CD, actual stability constants would be of great interest; however, it is
not evident to calculate a stability constant in complex media such as
intestinal fluids since the equilibrium between itraconazole and cyclo-
dextrins will be affected by interactions between itraconazole and bile
salt/phospholipid micelles, and between bile salts and cyclodextrins. As
the composition of intestinal fluids is continuously changing over time
and the intestinal samples were aspirated time-dependently, these in-
teractions will differ in each intestinal aspirate. Moreover, pH highly
affects ionization behavior of itraconazole and as a result the affinity for
complexation with HP-β-CD. Since pH fluctuated (range 3.5–7.7)
among the different intestinal aspirates, this implies that the interaction
between itraconazole and HP-β-CD differs in each intestinal aspirate,
again complicating the calculation of a meaningful stability constant.
Despite the fact that the data strongly support the importance of
cyclodextrins in stabilizing itraconazole solutions in the duodenum, it
should be emphasized that other factors (e.g. bile salts) may affect the
dissolved fraction as well [20].
In contrast to the remarkable impact of water intake on duodenal
itraconazole concentrations, the combined systemic exposure of itra-
conazole and its active metabolite hydroxy-itraconazole was almost
unaffected, as reported previously [17]. In HV02, systemic concentra-
tions were even decreased when the formulation was administered
without water (Fig. 5), despite a strong increase in duodenal con-
centrations (6.4-fold). Presumably, the stronger interaction at higher
HP-β-CD concentrations reduces the free fraction of the drug that is
available to cross the intestinal epithelium. Indeed, higher HP-β-CD
concentrations were measured when Sporanox® was administered
without water invigorating the hypothesis that the extent of entrapment
of itraconazole in the concentration-dependent cyclodextrin complexes
determines the intestinal absorption. It should be noted that HP-β-CD is
not absorbed from the gastrointestinal tract due to its size and hydro-
philic nature [24].
To directly explore the influence of HP-β-CD on the intestinal per-
meation of itraconazole, aliquots (500 µL) of freshly aspirated duodenal
fluids were, as previously reported [17], immediately applied to the
donor side of a Caco-2 cell system. Since the concentrations of HP-β-CD
were unknown at the time of the initial study, permeated itraconazole
data were only suggestive for a higher extent of entrapment at higher
HP-β-CD concentrations. Based on the measured concentrations of HP-
β-CD in the intestinal samples, the hypothesis that higher HP-β-CD
concentrations reduce the free drug fraction appears to be justified. As
illustrated in Fig. 6, high HP-β-CD concentrations were measured in
samples where a lower percentage of itraconazole (relative to the
amount present in the donor compartment) reached the basolateral
medium indicating that an increase in donor itraconazole concentration
did not result in a proportionally increased transport of itraconazole.
Conversely, lower HP-β-CD concentrations were accompanied with a
higher permeated fraction of itraconazole. As such, these data affirm
the impact of cyclodextrins on the intestinal permeation of itraconazole
by the formation of concentration-dependent inclusion complexes that
impede the intestinal permeation of the lipophilic drug.
Overall, the current data established that quantification of HP-β-CD
concentrations in the intestinal samples is essential to interpret the
intraluminal behavior of itraconazole upon oral administration of a
highly concentrated HP-β-CD-based solution with a different volume of
water (0 mL vs. 240mL). Moreover, the data obtained substantiate the
hypothesis that cyclodextrins are able to enhance intraluminal con-
centrations of itraconazole but may simultaneously reduce the free
fraction of the drug available for permeation.
4. Conclusion
Since pharmaceutical excipients may fundamentally affect gastro-
intestinal drug behavior, in-depth gastrointestinal formulation evalua-
tion benefits from their assessment. In this respect, concentrations of
the solubilizing agent HP-β-CD were quantified, for the first time, in
human duodenal fluids upon the oral administration of a highly con-
centrated HP-β-CD solution. Linking the intestinal concentrations of
HP-β-CD to itraconazole concentrations helps to understand in-
traluminal formulation behavior as illustrated by the fact that in-
traluminal itraconazole concentrations are not necessarily freely
available for permeation in the presence of cyclodextrins by the for-
mation of inclusion complexes. Since knowledge about physiologically
relevant HP-β-CD concentrations in the small intestine is limited, the
measured concentrations of HP-β-CD might be useful as reference data
to support the development of predictive in vitro and in silico tools.
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